These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

489 related articles for article (PubMed ID: 9397382)

  • 1. Benefits of hormone replacement therapy--overview and update.
    Calaf i Alsina J
    Int J Fertil Womens Med; 1997; 42 Suppl 2():329-46. PubMed ID: 9397382
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estrogen replacement therapy in the elderly.
    Paganini-Hill A
    Zentralbl Gynakol; 1996; 118(5):255-61. PubMed ID: 8701621
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Postmenopausal hormone therapy and the risk of cardiovascular disease.
    Stramba-Badiale M
    J Cardiovasc Med (Hagerstown); 2009 Apr; 10(4):303-9. PubMed ID: 19430340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A decision tree for the use of estrogen replacement therapy or hormone replacement therapy in postmenopausal women: consensus opinion of The North American Menopause Society.
    Menopause; 2000; 7(2):76-86. PubMed ID: 10746889
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hormone replacement therapy: controversies, pros and cons.
    Warren MP; Halpert S
    Best Pract Res Clin Endocrinol Metab; 2004 Sep; 18(3):317-32. PubMed ID: 15261840
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hormone replacement therapy in postmenopausal women.
    Yasui T; Uemura H; Takikawa M; Irahara M
    J Med Invest; 2003 Aug; 50(3-4):136-45. PubMed ID: 13678382
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Postmenopausal osteoporosis and hormone replacement therapy.
    Gambacciani M; Vacca F
    Minerva Med; 2004 Dec; 95(6):507-20. PubMed ID: 15785435
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The risks and benefits of estrogen replacement therapy: Leisure World.
    Paganini-Hill A
    Int J Fertil Menopausal Stud; 1995; 40 Suppl 1():54-62. PubMed ID: 7581589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hormone replacement therapy and cancer.
    Gynecol Endocrinol; 2001 Dec; 15(6):453-65. PubMed ID: 11826770
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term estrogen and hormone replacement therapy for the prevention and treatment of osteoporosis.
    Levine JP
    Curr Womens Health Rep; 2003 Jun; 3(3):181-6. PubMed ID: 12734027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Controversial issues in climacteric medicine II. Hormone replacement therapy and cancer. International Menopause Society Expert Workshop. 9-12 June 2001, Opera del Duomo, Pisa, Italy.
    Genazzani AR; Gadducci A; Gambacciani M
    Climacteric; 2001 Sep; 4(3):181-93. PubMed ID: 11588941
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hormone replacement therapy in postmenopausal women.
    Prelevic GM; Kocjan T; Markou A
    Minerva Endocrinol; 2005 Mar; 30(1):27-36. PubMed ID: 15877011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic features of menopausal and postmenopausal applicants for life insurance.
    Schiefeling M
    J Insur Med; 1996; 28(1):27-34. PubMed ID: 10172866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hormone replacement therapy in the post-Women's Health Initiative era. Report a a meeting held in Funchal, Madeira, February 24-25, 2003.
    Burger H
    Climacteric; 2003 May; 6 Suppl 1():11-36. PubMed ID: 12945798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Climacteric medicine: European Menopause and Andropause Society (EMAS) 2004/2005 position statements on peri- and postmenopausal hormone replacement therapy.
    Skouby SO; Al-Azzawi F; Barlow D; Calaf-Alsina Erdogan Ertüngealp J; Gompel A; Graziottin A; Hudita D; Pines A; Rozenberg S; Samsioe G; Stevenson JC;
    Maturitas; 2005 May; 51(1):8-14. PubMed ID: 15883103
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drospirenone and estradiol: a new option for the postmenopausal woman.
    Archer DF
    Climacteric; 2007 Feb; 10 Suppl 1():3-10. PubMed ID: 17364592
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extended hormone replacement: who should get it, and for how long?
    Langer RD; Barrett-Connor E
    Geriatrics; 1994 Dec; 49(12):20-4; 29. PubMed ID: 7982582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recency and duration of postmenopausal hormone therapy: effects on bone mineral density and fracture risk in the National Osteoporosis Risk Assessment (NORA) study.
    Barrett-Connor E; Wehren LE; Siris ES; Miller P; Chen YT; Abbott TA; Berger ML; Santora AC; Sherwood LM
    Menopause; 2003; 10(5):412-9. PubMed ID: 14501602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Investigative models for determining hormone therapy-induced outcomes in brain: evidence in support of a healthy cell bias of estrogen action.
    Brinton RD
    Ann N Y Acad Sci; 2005 Jun; 1052():57-74. PubMed ID: 16024751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hormone replacement therapy and risk for coronary heart disease. Data from the CORA-study--a case-control study on women with incident coronary heart disease.
    Windler E; Zyriax BC; Eidenmüller B; Boeing H
    Maturitas; 2007 Jul; 57(3):239-46. PubMed ID: 17292571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.